Pfizer (PFE) Soars on Tariff Exemption, Landmark US Govt Deal

Group 1 - Pfizer Inc. has seen a significant stock price increase, rising 6.83% to close at $25.48, following the announcement of its exemption from a 100% tariff on pharmaceutical imports by the US government [1][4] - The company has reached a landmark agreement with the US government to lower prescription drug costs for American patients, ensuring that drug prices are comparable to those in other developed countries [2] - Pfizer will participate in a direct purchasing platform, TrumpRx.gov, allowing American patients to purchase medicines at discounts of up to 85% and an average of 50% on select treatments [3] Group 2 - The agreement with the US government exempts Pfizer from the impending 100% tariff on pharmaceutical imports, effective October 1 [4]